from Reuters: Health News https://reut.rs/2zxvBBR
Sunday, December 2, 2018
High-cost Gilead cell therapy proves durable for some lymphoma patients
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday.
from Reuters: Health News https://reut.rs/2zxvBBR
from Reuters: Health News https://reut.rs/2zxvBBR
Subscribe to:
Post Comments (Atom)
-
(Reuters Health) - More than half of heart failure patients who visit the emergency room don't receive prompt follow-up care, and a Cana...
-
WEIGHT LOSS supplements could help overweight or obese patients with the diet plans. You could lose weight and avoid weight gain by adding...
-
A U.S. appeals court on Wednesday declined a request by Johnson & Johnson for an temporary restraining order blocking sales of generic v...
No comments:
Post a Comment